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.2012.11Abstract The prevalence of cardiovascular disease is growing rapidly in developing countries, lead-
ing to an increasing incidence of acute coronary syndrome (ACS). The modalities available for diag-
nosing and treating this disease continue to evolve, and considerations must be made
of local resources when making diagnostic and therapeutic choices. This article provides an
evidence-based guide to the management of ACS, with speciﬁc recommendations for clinicians work-
ing in low and middle-income countries (LAMICs). Diagnosis of ACS, including both non ST-eleva-
tion (NSTE) and ST elevation (STE) ACS, focuses on risk stratiﬁcation, vigilance for subtle or
atypical presentations, and consideration of alternative causes of chest pain. The diagnostic process
involves assessment of risk factors, knowledge of high yield history and physical exam ﬁndings
(including variations that may exist in various populations), and utilization of appropriate diagnostic
tests. Aspirin should be used as initial treatment in conjunction with an additional anti-platelet drug.
Prasugrel is preferred over clopidogrel if the patient is having STE-ACS and planned for percutaneous
coronary intervention (PCI). Bivalirudin should be the ﬁrst choice for anti-coagulation in STE-ACS,
followed by enoxaparin (which does not require a drip), and then unfractionated heparin. For the
patient with NSTE-ACS and an increased bleeding risk, fondaparinux should be considered in place
of enoxaparin. Oxygen should be administered to patients with breathlessness, signs of heart failure,
shock, or arterial oxyhemoglobin saturation less than 94%. Beta blockade should be given if there are
no signs of instability such as heart rate greater than 100 beats per minute or hypotension. Nitrates or
morphine may be given to control symptoms, but do not confer morbidity or mortality advantages3312587.
m (A. Koyfman).
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Diagnosis and management of acute coronary syndrome 125and are therefore not critical if a patient is comfortable. PCI should be performed if indicated and
available. Fibrinolysis should be administered instead if delay to PCI would be greater than 90 min.
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Chest painAbstract La pre´valence des maladies cardiovasculaires connaıˆt une croissance rapide dans les pays en
de´veloppement, entraıˆnant une incidence croissante du syndrome coronarien aigu (SCA). Lesmodalite´s
de diagnostic et de traitement de cette maladie continuent d’e´voluer, et il convient de tenir compte des
ressources locales lors de la re´alisation d’un diagnostic et la de´termination des options the´rapeutiques.
Cet article constitue un guide a` la prise en charge du SCA fonde´ sur l’expe´rience, et fournit des recom-
mandations spe´ciﬁques destine´es auxme´decins hospitaliers travaillant dans les pays a` bas et moyen rev-
enu.Le diagnostic duSCA, y compris les SCA sans e´le´vationduSTet avec e´le´vationduST, se concentre
sur la stratiﬁcation du risque, la vigilance relative auxmanifestations subtiles ou atypiques, et la prise en
conside´rationd’autres causes des douleurs poitrinaires. Leprocessus dediagnostic implique l’e´valuation
des facteurs de risque, la connaissancedes ante´ce´dentsme´dicauxde´favorables et les conclusions de l’exa-
men physique (des variantes e´tant susceptibles d’exister dans les diffe´rentes populations), ainsi que l’util-
isation de tests de diagnostic approprie´s. Il est recommande´ d’utiliser de l’aspirine a` titre de traitement
initial, paralle`lement a` un antiagre´gant plaquettaire supple´mentaire. Le prasugrel est pre´fe´re´ au clopi-
dogrel si le patient pre´sente un SCA avec e´le´vation du ST et qu’une intervention coronaire percutane´e
(ICP) est pre´vue. La bivalidurine devrait eˆtre le premier choix pour e´viter la coagulation dans les SCA
avec e´le´vation du ST, suivie de l’enoxaparine (qui ne ne´cessite pas de perfusion), puis d’he´parine non
fractionne´e. Pour les patients pre´sentant un SCA sans e´le´vation du ST et en cas de risque de saignement
accru, le fondaparinux devrait eˆtre envisage´ a` la place de l’e´noxaparine. Les patients souffrant de dys-
pne´e, pre´sentant des signes d’insufﬁsance cardiaque, de choc ou de saturation oxyhe´moglobine´e arte´ri-
elle infe´rieure a` 94% doivent se voir administrer de l’oxyge`ne. Des beˆtabloquants ne devraient eˆtre
administre´s que dans le cas ou` aucun signe d’instabilite´ n’est observe´, comme un rythme cardiaque sup-
e´rieur a` 100 pulsations par minute ou de l’hypotension. Des nitrates ou de la morphine peuvent eˆtre
administre´s aﬁn de controˆler les symptoˆmes mais n’apportent aucun be´ne´ﬁce en termes de morbidite´
ou de mortalite´, et ne sont donc pas essentiels si le patient n’est pas mal a` l’aise. Une ICP ne devrait eˆtre
re´alise´e que si cela est indique´ et qu’une telle intervention est disponible. Une ﬁbrinolyse devrait eˆtre re´a-
lise´e a` la place si le de´lai pour re´aliser une ICP est supe´rieur a` 90 min.
ª 2013 Production and hosting by Elsevier on behalf of African Federation for Emergency Medicine.Introduction
Cardiovascular disease (CVD) is the most common cause of
mortality in the world, resulting in over 17 million deaths
annually.1 This disease state can take on many different man-
ifestations, such as rheumatic heart disease, heart failure,
hypertension, stroke, and coronary artery disease (CAD). Cor-
onary artery disease, which can cause acute coronary syn-
drome (ACS), is responsible for nearly half of the total
worldwide deaths attributable to CVD.2 In Africa, CVD is sec-
ond only to infectious diseases as the most frequent etiology of
death, and is the source of a substantial degree of chronic ill-
ness and disability.3
In spite of being largely preventable with modiﬁcation of
risk factors and appropriate medical therapy, the overall glo-
bal prevalence of CVD and CAD is anticipated to rise in the
coming years. These trends will disproportionately affect
developing countries, and it is projected that the burden of
these diseases in Africa will double.3 State of the art treatment
is costly – the United States spends approximately $300 billion
annually on CVD, a cost that is expected to triple by 2030.4
Even when faced with limited resources, however, many effec-
tive interventions remain available to emergency physicians
and other acute care providers for the management of ACS.Pathophysiology
Acute coronary syndrome is broken down based on the pres-
ence or absence of ST elevations on the patient’s electrocardio-
gram (ECG). Atherosclerotic plaques accumulate within the
coronary arteries over time, with stenotic lesions of at least
60% resulting in ischemia to the myocardium with exertion.
These unstable lipid-rich plaques may acutely rupture, leading
to platelet activation and formation of a thrombus. This pro-
cess may cause a sudden stenosis or frank occlusion, which
in turn restricts blood ﬂow to the myocardium and, coupled
with vasospasm and reperfusion injury, leading to myocyte
death.5
Deﬁnition
As set forth by the Global Myocardial Infarction (MI) Task
Force, the deﬁnition of MI has been reﬁned multiple times
to account for the increasing sensitivity of biomarker assays
(i.e., cardiac troponin) and the variety of conditions in which
these biomarkers may be present. Fundamentally, the diagno-
sis requires evidence of myocardial necrosis in a clinical setting
consistent with myocardial ischemia. The most recent revision
of these guidelines include separate thresholds for cardiac tro-
126 B. Hamilton et al.ponin in peri-procedural patients, speciﬁcally in the context of
recent percutaneous coronary intervention (PCI) or coronary
artery bypass grafting (CABG).6
The clinical and epidemiological need for a deﬁnition of MI
that does not require cardiac biomarker testing for use in re-
source-constrained settings has been acknowledged, and addi-
tional criteria have been developed by the WHO (Table 1).
Fulﬁlling the diagnosis of a ‘‘probable MI’’ outlined in Cate-
gory C of Table 1 involves ruling out alternative explanations
for the patient’s symptoms, strategies for which are discussed
below.
Diagnosis
The diagnosis of ACS can pose a difﬁcult clinical challenge.
The presenting complaints can be myriad and atypical, and
even a classic description of ischemic chest pain may in fact
represent a pulmonary embolus, an aortic dissection, or an-
other life-threatening process (Tables 2 and 3). Vital signs
and addressing the ABC’s are the ﬁrst step in the approach
to these patients. Obtaining a rapid history and physical exam
with particular attention paid to breath sounds, heart sounds,
the presence of jugular venous distension, and peripheral
circulation can help rule in or rule out time-sensitive diagnoses
like tension pneumothorax and pericardial tamponade
(Table 2).
An important early objective in working up patients pre-
senting with potential ACS is risk stratiﬁcation. Although no
decision rule exists that allows one to deﬁnitively exclude the
diagnosis of ACS based solely on history, ECG, and a single
measurement of biomarkers, having knowledge of risk factors
(Tables 3 and 4) and being able to appropriately stratify a pa-
tient will aid the physician in the interpretation of subsequent
test results as well as in determining the disposition.8
Risk stratiﬁcation should begin by screening for diagnoses
that require emergent intervention, and an ECG should be
the initial screening tool to look for evidence of ischemic heart
disease. The management algorithm will be determined by the
presence or absence of ST elevations (STE-ACS, also known
as STEMI) (Table 5), although in the patient with persisting
chest pain and a negative initial ECG, serial studies may reveal
an early and evolving AMI. Prolonged ‘‘door-to-ECG’’ times
greater than 10 min have been linked with adverse clinical out-
comes in patients presenting with STE-ACS.12
Additional ECG features, such as left bundle-branch
blocks (LBBB), may make a clear-cut diagnosis of STE-
ACS difﬁcult. Some ST-segment patterns are suggestive of
an MI in this setting: 1. ST-segment pattern 1 mm or greater
and concordant (in the same direction as the main deﬂection)
with the QRS complex, 2. ST-segment depression 1 mm or
more in leads V1, V2, or V3, or 3. ST-segment elevation
5 mm or greater and discordant with the QRS complex.13 If
suspicion for an MI is high in a patient with an LBBB that
is presumed to be new (or similarly, if ventricular pacing is
present), the patient should be considered for immediate
angiography and reperfusion.14
Serum cardiac biomarkers should be obtained if available,
although therapy should not wait for these results in the pres-
ence of STE-ACS. The recent development of highly sensitive
troponin assays will enable the physician to detect the presence
(or absence) of an acute myocardial infarction within 3 h ofonset, rather than the 6–8 h required with traditional tropo-
nin-I assays.15
Ancillary imaging studies such as chest X-ray and cardiac
ultrasound can aid in further reﬁning of the differential diag-
nosis. More sophisticated imaging tests, such as CT coronary
angiography, have been demonstrated to provide a reliable
anatomical basis for excluding ACS and to allow safe, expe-
dited discharge from the ED.18
If the ECG is not diagnostic of STE-ACS and cardiac
biomarkers are positive, the patient can be diagnosed as
having non-ST-elevated ACS (NSTE-ACS, also known as
NSTEMI). If both ECG and serial biomarkers are negative,
deﬁnitive ruling in or out of ACS may require a stress
test.19 Alternatively, in a patient who is at medium or high
risk, coronary angiography can deﬁne the extent of the cor-
onary lesions as well as provide a means of re-establishing
patency.Management – pharmacology
The management of all forms of ACS is directed toward
reversing the pathogenic platelet activation, thrombus forma-
tion, and vasospasm, with the goal of restoring perfusion to
the distal myocardium. The primary intervention in a case of
suspected or conﬁrmed ACS is aspirin therapy, which targets
platelet activation by irreversibly inhibiting cyclooxygenase
1-mediated thromboxane A2 synthesis.20 This treatment
alone can provide a reduction in mortality of approximately
25%.16,21
In addition to aspirin administration as early out-of-hospi-
tal or emergency department management, laboratory studies
have suggested that augmenting the metabolic substrate for
ischemic myocardium could mitigate the extent of an eventual
infarction. The IMMEDIATE trial studied the effect of giving
glucose-insulin-potassium in the pre-hospital setting for sus-
pected ACS, but did not ﬁnd a difference in progression to
MI or 30-day mortality when compared with glucose pla-
cebo.22 Routine oxygen therapy, even in the absence of hypox-
ia, would seem to be an intuitively beneﬁcial intervention for
similar reasons, although the limited trials to date have not
supported this practice and have even suggested the possibility
of harm.23,24
Pain control should be addressed early through relief of
myocardial stress and promotion of enhanced oxygen delivery.
Nitroglycerin facilitates both of these goals through coronary
artery dilation and redistribution of blood to ischemic regions,
and is the ﬁrst line therapy in the absence of hypotension or
right ventricular infarction.25 Morphine is considered second-
line treatment, although it has not been shown to improve out-
comes and in one observational study was associated with a
higher adjusted risk of mortality.26 Beta blockers are not rec-
ommended early in the course of an acute MI if risk factors
are present for the development of cardiogenic shock, such
as heart rate greater than 100 beats per minute or any episodes
of hypotension.27
Antagonists to the platelet P2Y12 ADP receptor, such as
clopidogrel and prasugrel, have also been shown to have ben-
eﬁt, both as monotherapy and when used in combination with
aspirin. This dual antiplatelet approach is one of the corner-
stones of current therapy, although the commensurate risk of
Table 1 Criteria for acute myocardial infarction by setting (reproduced).6,7
Category A: Settings without resource constraints
 Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least one
value above the 99th percentile upper reference limit (URL) and with at least one of the following:
o Symptoms of ischemia.
o New or presumed new signiﬁcant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB).
o Development of pathological Q waves in the ECG.
o Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.
o Identiﬁcation of an intracoronary thrombus by angiography or autopsy.
 Cardiac death with symptoms suggestive of myocardial ischemia and presumed new ischemic ECG changes or new
LBBB, but death occurred before cardiac biomarkers were obtained, or before cardiac biomarker values would be
increased.
 Percutaneous coronary intervention (PCI) related MI is arbitrarily deﬁned by elevation of cTn values (>5 · 99th
percentile URL) in patients with normal baseline values (699th percentile URL) or a rise of cTn values >20% if
the baseline values are elevated and are stable or falling. In addition, either (i) symptoms suggestive of myocardial
ischemia or (ii) new ischemic ECG changes or (iii) angiographic ﬁndings consistent with a procedural complication
or (iv) imaging demonstration of new loss of viable myocardium or new regional wall motion abnormality are
required.
 Stent thrombosis associated with MI when detected by coronary angiography or autopsy in the setting of myocar-
dial ischemia and with a rise and/or fall of cardiac biomarker values with at least one value above the 99th percen-
tile URL.
 Coronary artery bypass grafting (CABG) related MI is arbitrarily deﬁned by elevation of cardiac biomarker values
(>10 · 99th percentile URL) in patients with normal baseline cTn values (699th percentile URL). In addition,
either (i) new pathological Q waves or new LBBB, or (ii) angiographic documented new graft or new native cor-
onary artery occlusion, or (iii) imaging evidence of new loss of viable myocardium or new regional wall motion
abnormality.
Category B: Settings without cardiac biomarkers
 Both of the following criteria are present:
o Symptoms of ischemia (ischemic symptoms include various combinations of chest, upper extremity, jaw or epi-
gastric discomfort with exertion or at rest; the discomfort usually lasts 620 min, often is diffuse, not localized,
not positional, not affected by movement of the region, and it may be accompanied by dyspnea, diaphoresis,
nausea or syncope).
o Development of unequivocal pathological Q waves (no pathological Q wave in the ﬁrst ECG or in the event set
of ECG/s followed by a record with a pathological Q wave––any Q wave in leads V2–V3P0.02s or QS complex
in leads V2 and V3. Q-waveP0.03s andP0.1 mV deep or QS complex in leads I, II, aVL, aVF or V4–V6 in any
two leads of a contiguous lead grouping I, aVL, V6: V4–V6: II, III, aVF).
 Or, death with a history of coronary heart disease and/or documented cardiac pain within 72 h before death and no
evidence of non-coronary cause of death, or autopsy evidence of chronic coronary heart disease, including coronary
atherosclerosis and myocardial scarring.
Category C: Settings without means of utilizing categories A or B (probable MI)
 Either one of the following is present in a person with symptoms of ischemia (described above), without evidence of
a non-coronary reason:
o Development of unequivocal pathological Q waves.
o Incomplete information on cardiac biomarkers (preferably troponin) provided that myocardial damage of other
reasons and other clinical considerations that can cause a rise in cardiac biomarkers are excluded.
 Or, autopsy ﬁndings suggestive of MI but not conclusive.
Diagnosis and management of acute coronary syndrome 127bleeding can be substantial.20 Currently, clopidogrel is com-
monly used in the setting of NSTE-ACS, while prasugrel
has demonstrated marginal superiority in STE-ACS patients
undergoing PCI.28 The on-going Trilogy ACS study is compar-
ing both agents in the setting of NSTE-ACS and ﬁndings are
anticipated in the second half of 2012.29
Recent trials looking at more efﬁcacious 2nd generation
P2Y12 antagonists, such as ticagrelor, and PAR-1 thrombin
antagonists (so-called ‘‘triple therapy’’) have found success in
outcomes from ischemic heart disease, but have also noted
serious complications from heightened bleeding risk, particu-
larly in patients with prior stroke.30GPIIb/IIIa inhibitors prevent platelet aggregation via the
ﬁbrinogen receptor. These agents are helpful at the time of
PCI but not when given up-front in the emergency depart-
ment or if ﬁbrinolysis is pursued.16 Anticoagulation therapy
such as unfractionated heparin, enoxaparin, or fondaparinux
is useful prior to PCI or ﬁbrinolysis. Bivalirudin is an antico-
agulant that eliminates the need for simultaneous administra-
tion of a GPIIb/IIIa inhibitor, and as part of pre-hospital
treatment of STE-ACS was found to signiﬁcantly reduce
the rate of CV events when compared with abciximab and
heparin.31
Table 2 Immediate and life-threatening causes of chest pain.8
Acute coronary syndrome Pericarditis with tamponade
Pulmonary embolism Tension pneumothorax
Esophageal rupture Aortic dissection
Table 4 Risk factors for CAD chieﬂy derived from an
international population.10,11
DiabetesHypertension Age and sex
Hypercholesterolemia Obesity
Family history of CAD Smoking history
Table 5 STE-ACS (STEMI) diagnostic criteria
(reproduced).16,17.
American College of Cardiology/American Heart Association ST-
Segment Elevation Myocardial Infarction (STEMI) Diagnosis
GuidelinesIn a patient presenting with active chest pain, a 12-lead
128 B. Hamilton et al.Lipid-lowering therapy (HMG-CoA reductase inhibition)
has been demonstrated to be a powerful adjunct in secondary
prevention of cardiovascular events.32 Statins should be
started on all patients who suffer from an acute MI early in
their hospital admission, irrespective of cholesterol concentra-
tion. Best available evidence suggests high-dose treatment with
atorvastatin if tolerated by the patient.14electrocardiogram showing:
1. ST-segment elevation P1 mm (0.1 mV) in 2 or more adjacent
limb leads
2. ST-segment elevation P1 mm (0.1 mV) in precordial leads V4
through V6
3. ST-segment elevation P2 mm (0.2 mV) in precordial leads V1
through V3, or
4. New left bundle-branch blockTherapy should not be delayed
while awaiting results of cardiac biomarkers. Reciprocal
depressions (ST depressions in the leads corresponding to the
opposite side of the heart) make the diagnosis of STEMI more
speciﬁc.Management – PCI/ﬁbrinolysis
The rationale for the difference in approach to STE-ACS ver-
sus NSTE-ACS is the rapidity with which blood ﬂow must be
re-established in the former to avoid irreversible transmural
damage. Mortality outcomes in the event of STE-ACS worsen
signiﬁcantly with delay to time of deﬁnitive treatment, prompt-
ing the American College of Cardiology/American Heart
Association recommendations that door-to-balloon time (from
ED arrival to the catheterization lab) and door-to-needle time
(ED arrival to ﬁbrinolysis) optimally occur within 90 min and
30 min, respectively.33–35
The challenge posed by meeting the 30 min target for ﬁbri-
nolysis was analyzed in a study by Maharaj et al. of 3 hospitals
in Cape Town, which found a median door-to-needle time of
54 min. The timing was comparable to that reported by medi-
cal centers in the Middle East, Pakistan, India, and Vancouver,
and identiﬁed atypical presentations, system delays, and lack
of appropriately trained clinicians as barriers.35
Many ﬁbrinolytic agents exist, although the choice of drug
is less important than the rapidity with which it is adminis-
tered.34 First generation medications such as streptokinase
are antigenic, resulting in allergic reactions in approximately
6% of patients treated. Alteplase, also known as tissue plas-
minogen activator (tPA), is second generation and has a short-
er half-life (<5 min), requiring IV infusion over 60–90 min.Table 3 Value of chest pain symptoms toward likel
Pain descriptor
Increased likelihood of AMI
 Radiation to right arm or shoulder
 Radiation to both arms or shoulders
 Associated with exertion
 Radiation to left arm
 Associated with diaphoresis
 Associated with nausea or vomiting
 Worse than previous angina or similar to previous M
 Described as pressure
Decreased likelihood of AMI
 Described as pleuritic
 Described as positional
 Described as sharp
 Reproducible with palpation
 Inframammary location
 Not associated with exertionThe third generation ﬁbrinolytics such as reteplase and tenec-
teplase have the advantage of allowing for weight-based bolus
administration36, of the two, tenecteplase is often preferred, as
it requires only a single dose.
Percutaneous coronary intervention (PCI) has been shown
to be superior to ﬁbrinolytic drug therapy both in reduction
of mortality from re-infarction and need for eventual coronary
artery bypass grafting.35 Availability of PCI has historically
been based at hospitals with on-site capability to perform car-
diac surgery, making ﬁbrinolysis the default option for deﬁni-
tive therapy at many institutions worldwide. This paradigm
may currently be changing with the impressive safety proﬁle
of international centers performing primary PCI without surgi-
cal backup.37ihood of acute myocardial infarction (AMI).9
Positive likelihood Ratio (95% CI)
I
 4.7 (1.9–12)
 4.1 (2.5–6.5)
 2.4 (1.5–3.8)
 2.3 (1.7–3.1)
 2.0 (1.9–2.2)
 1.9 (1.7–2.3)
 1.8 (1.6–2.0)
 1.3 (1.2–1.5)
 0.2 (0.1–0.3)
 0.3 (0.2–0.5)
 0.3 (0.2–0.5)
 0.3 (0.2–0.4)
 0.8 (0.7–0.9)
 0.8 (0.6–0.9)
Table 6 Absolute contraindications for ﬁbrinolysis use in ST-
elevation myocardial infarction.14,34.
Any prior intracranial hemorrhage
Known structural cerebral vascular lesion (e.g. AVM)
Known malignant intracranial neoplasm (primary or metastatic)
Ischemic stroke within 6 months
EXCEPT acute ischemic stroke within 3 h
Suspected aortic dissection
Active bleeding or bleeding diathesis (excluding menses)
Signiﬁcant trauma/surgery/head injury (within preceding 3 weeks)
Gastrointestinal bleeding within the past month
Non-compressible punctures in the past 24 h (e.g. liver biopsy,
lumbar puncture)
ICH, intracranial hemorrhage; AVM, arteriovenous malformation
Diagnosis and management of acute coronary syndrome 129In South Africa as a whole, the ACCESS study found that
ﬁbrinolysis was performed in the minority of patients, even in
the absence of contraindications (Table 6). This choice of ther-
apeutic strategy was speculated to be due to the accessibility of
urgent angiography in the 29 participating sites. Overall, these
hospitals were aggressive in pursuing invasive treatment rela-
tive to other countries included in the larger ACCESS registry,
but also had favorable 1-year mortality outcomes and lower
rates of re-admission for bleeding and recurrent ischemic
events.38
Special considerations
Therapeutic hypothermia
Therapeutic hypothermia (TH) can preserve neurologic func-
tion in a comatose patient following cardiac arrest, as well as
provide cardiac protection by limiting infarct size in the event
of STE-ACS. One of the main obstacles to more widespread
use of TH in this context is the potential for delay to PCI,
due to difﬁculties in rapid cooling to the goal temperature of
32–36 degrees centigrade. Intravenous infusion of refrigerated
ﬂuids is the quickest way to achieve this temperature, although
newer surface, intranasal, and peritoneal cooling devices are
currently being investigated.39
Renal Dysfunction
The presence of renal dysfunction may serve as an indepen-
dent risk factor for CVD. In a study by Chang et al., pa-
tients presenting to the ED with undifferentiated chest pain
and comorbid renal insufﬁciency were at an increased 30-
day risk of all cause CV events, including death, nonfatal
AMI, and revascularization. Patients with an established
diagnosis of ACS and renal insufﬁciency have been shown
to have worse in-hospital mortality, even when adjusted for
other factors.40
Human immune deﬁciency virus (HIV)
HIV has been documented to confer risk of premature CAD
and ACS. The virus itself can promote atherosclerosis through
dyslipidaemia, endothelial dysfunction, and inﬂammation, as
well as derangement of the coagulation proﬁle leading to a
pro-thrombotic state. Protease inhibitors, as a component of
highly active antiretroviral therapy, are known to have similar
effects. Consequently, patients with HIV, regardless of treat-
ment status, may present with ACS at a younger age and with
fewer traditional risk factors.41,42Substance abuse
Cocaine use is a common precipitant of chest pain and ACS,
particularly in younger patients presenting to the ED. The
pathophysiology of ACS development in this population de-
pends on the same processes as in non-cocaine associated
ACS, although the causal relationship between cocaine use
and development of CAD has been debated in the literature.
The largest study to date has concluded that cocaine use has
not been shown to be independently associated with clinically
signiﬁcant CAD.43Similarly, a study by Ali et al. looked at the characteristics
and outcomes of patients with ACS who also chewed khat, a
plant with stimulant properties that is thought to induce coro-
nary artery spasm. These patients were noted to have fewer CV
risk factors and were less likely to have a history of CAD, but
were more likely to present with STE-ACS and had worse
overall outcomes over the course of 1 year.44
Treatment summary, by therapeutic category
See Table 7 for recommended drug doses.
Antiplatelet therapy
Aspirin therapy should be given to all patients with suspected
ACS (unless allergic or active gastrointestinal hemorrhage
present)
 NSTE-ACS: Additionally, administer clopidogrel.
o STE-ACS: If patient going for primary PCI, use
prasugrel.
o If prasugrel unavailable or patient is not going for PCI,
use clopidogrel.Anticoagulation
 NSTE-ACS: Enoxaparin has the best level of evidence and
safety proﬁle for initial anticoagulation.
o If patient at increased bleeding risk, consider fondapar-
inux in place of enoxaparin.
o If enoxaparin and fondaparinux unavailable, use
unfractionated heparin, titrating to aPTT between 50
and 70.
 STE-ACS: If PCI planned, use bivalirudin.
o If bivalirudin unavailable, or if there is no plan for PCI,
use enoxaparin.
o If enoxaparin unavailable, use unfractionated heparin.Supportive care
STE-ACS or NSTE-ACS
 Provide supplemental oxygen to patients with breathless-
ness, signs of heart failure, shock, or an arterial oxyhemo-
globin saturation <94%.
Table 7 Drug dosages in treatment of ACS.14,45,46.
Antiplatelet therapy
Aspirin 160–325 mg (non-enteric coated)
Clopidogrel 300–600 mg PO
Prasugrel 60 mg PO
Anticoagulation therapy
Unfractionated heparin
Loading dose
60 units/kg
IV, followed
by 12 units/
kg/h IV
Enoxaparin NSTE-ACS: 1 mg/kg SCSTE-ACS: 1 mg/kg SC + 30 mg IV
Fondaparinux 2.5 mg SC
Bivalirudin 0.75 mg/kg IV + 1.75 mg/kg/hour
Anti-ischemic/supportive therapy
Nitroglycerin 0.4 mg SL q5 min – up to 3 doses
Morphine 3 – 5 mg IV, repeat every few minutes PRN
Metoprolol 25 mg PO or 5 mg IV
Fibrinolytics
Tenecteplase Single weight-based bolus: 30–50 mg IV
Reteplase 10 units IV bolus, followed by another 10 units IV bolus 30 min later
Alteplase 15 mg IV bolus, followed by 0.75 mg/kg (not to exceed 50 mg)
infused · 30 min, then 0.50 mg/kg (not to exceed 35 mg) infused over 1 h
Streptokinase 1.5 million units infused over 1 h
Lipid-lowering therapy
Atorvastatin 80 mg daily
130 B. Hamilton et al. Administer sublingual nitroglycerin (NTG) if patient is
normotensive, does not have evidence of right ventricular
ischemia, and has on-going pain. Nitrates should not be
administered to patients with bradycardia (<50/min) or
tachycardia in the absence of heart failure (>100/min), or
to patients who have taken a phosphodiesterase inhibitor
for erectile dysfunction within 24 h (or 48 h if tadalaﬁl has
been used). If refractory, initiate IV NTG, titrating to
10% reduction in MAP (or 30% reduction if hypertensive).
 Intravenous morphine is reasonable to use if pain is not
relieved with NTG and the patient is not hypotensive or
hypovolemic.
 Beta blockers (for example, metoprolol) may be considered
if heart rate is 60–100 beats per minute, blood pressure is
normal or elevated, and there is no concern for current or
impending instability.
Revascularization
 STE-ACS: PCI is the optimal treatment modality if avail-
able within 90 min of presentation.
 If unable to perform within 90 min, or if unavailable, ﬁbri-
nolytics should otherwise be administered within 30 min of
presentation.
 Tenecteplase is a good ﬁrst choice, as it is dosed as a single
weight-based bolus.
 If tenecteplase is unavailable, alternatives include reteplase,
alteplase, or streptokinase, in order of decreasing
preference.
 NSTE-ACS: PCI is recommended for high-risk patients if it
can be performed within 48 h.Treatment summary, by diagnosis
See Table 7 for recommended drug doses.
NSTE-ACS or STE-ACS
 Aspirin therapy should be given to all patients with sus-
pected ACS (unless allergic or active gastrointestinal hem-
orrhage present).
 Provide supplemental oxygen to patients with breathless-
ness, signs of heart failure, shock, or an arterial oxyhemo-
globin saturation <94%.
 Administer sublingual nitroglycerin (NTG) if patient is nor-
motensive, does not have evidence of right ventricular ische-
mia, and has on-going pain. Nitrates should not be
administered to patients with bradycardia (<50/min) or
tachycardia in the absence of heart failure (>100/min), or
to patients who have taken a phosphodiesterase inhibitor
for erectile dysfunction within 24 h (or 48 h if tadalaﬁl has
been used). If refractory, initiate IV NTG, titrating to 10%
reduction in MAP (or 30% reduction if hypertensive).
 Intravenousmorphine is reasonable to use if pain is not relieved
with NTG and the patient is not hypotensive or hypovolemic.
 Beta blockers (for example, metoprolol) may be considered
if heart rate is 60–100 beats per minute, blood pressure is
normal or elevated, and there is no concern for current or
impending instability.NSTE-ACS
 Administer clopidogrel for additional anti-platelet therapy.
 Enoxaparin has the best level of evidence and safety proﬁle
for initial anticoagulation.
Diagnosis and management of acute coronary syndrome 131o If patient at increased bleeding risk, consider fondapar-
inux in place of enoxaparin.
o If enoxaparin and fondaparinux unavailable, use
unfractionated heparin, titrating to aPTT between 50
and 70.
 PCI is recommended for high-risk patients if it can be per-
formed within 48 h.
STE-ACS
 PCI is the optimal treatment modality if available within
90 min of presentation. If patient going for primary PCI:
o Administer prasugrel for additional anti-platelet
therapy.
n If prasugrel unavailable, use clopidogrel.
o Use bivalirudin for anticoagulation.
n If unavailable, use enoxaparin. If enoxaparin
unavailable, use unfractionated heparin. If unable to perform PCI within 90 min, or if unavailable,
ﬁbrinolytics should otherwise be administered within
30 min of presentation.
o Administer clopidogrel for additional anti-platelet
therapy.
o Use enoxaparin for anticoagulation. If unavailable, use
unfractionated heparin.
o Tenecteplase is a good ﬁrst choice for ﬁbrinolysis, as it is
dosed as a single weight-based bolus. If tenecteplase is
unavailable, alternatives include reteplase, alteplase, or
streptokinase, in order of decreasing preference.Conclusion
Extensive evidence has emerged from numerous clinical trials on
ACS. The studies described in this paper indicate that a combi-
nation of careful history, ECG interpretation, and cardiac en-
zymes can allow for the reliable diagnosis of ACS. Once
diagnosed, a concise set of treatments can signiﬁcantly improve
patient outcomes. The exact set of treatments underutilized can
be adjusted to local resource availability. There is currently a glo-
bal expansion of centers offering primary PCI for patients suffer-
ing STE-ACS, as well as the work toward broadening the
accessibility of essential pharmacotherapy, such as the efforts to-
ward the polypill.47 Though the burden of cardiovascular disease
and incidence of ACS are expected to increase in coming years,
emergency physicians and other acute care providers in any prac-
tice setting should feel well equipped to face them.African relevance
 In Africa, cardiovascular disease is second only to infec-
tious diseases as the most frequent etiology of death; this
paper describes current and projected acute coronary syn-
drome (ACS) epidemiology in Africa.
 Includes diagnostic and treatment algorithms based on
most current published data, with provision of alternative
strategies for clinicians in resource-limited settings.
 Offers insights into management of patients with comorbid-
ities frequently seen in Africa, such as HIV.What’s new?
 In Africa, coronary vascular disease is second only to infec-
tious disease as the most frequent etiology of death and its
prevalence is expected to double in coming years.
 Patients with HIV, regardless of treatment status, may pres-
ent with ACS at a younger age and with fewer traditional
risk factors.
 Fibrinolysis has traditionally been the default option for
deﬁnitive ACS therapy worldwide, although this paradigm
may be changing.Appendix A. Short answer questions
Test your understanding of the contents of this original paper
(answers can be found at the end of the regular features
section).
1. Which historical ﬁnding most increases the likelihood of an
acute myocardial infarction?
a. Described as pressure
b. Radiation to left arm
c. Associated with exertion
d. Radiation to right arm or shoulder
e. Similar to previous myocardial infarction
2. Which of the following is an absolute contraindication to
using ﬁbrinolysis in ST-elevation ACS?
a. Suspected aortic dissection
b. Signiﬁcant closed head trauma within 3 months
c. Known malignant intracranial neoplasm
d. Any prior ICH
e. All of the above
3. Which ﬁbrinolytic agent used for acute myocardial infarc-
tion can be administered as a single weight-based bolus?
a. Reteplase
b. Tenecteplase
c. sAlteplase
d. Streptokinase
e. UrokinaseReferences
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